Correlation Between Erytech Pharma and Molecular Partners

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Erytech Pharma and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Erytech Pharma and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Erytech Pharma SA and Molecular Partners AG, you can compare the effects of market volatilities on Erytech Pharma and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Erytech Pharma with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Erytech Pharma and Molecular Partners.

Diversification Opportunities for Erytech Pharma and Molecular Partners

0.01
  Correlation Coefficient

Significant diversification

The 3 months correlation between Erytech and Molecular is 0.01. Overlapping area represents the amount of risk that can be diversified away by holding Erytech Pharma SA and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Erytech Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Erytech Pharma SA are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Erytech Pharma i.e., Erytech Pharma and Molecular Partners go up and down completely randomly.

Pair Corralation between Erytech Pharma and Molecular Partners

If you would invest  564.00  in Molecular Partners AG on August 31, 2024 and sell it today you would earn a total of  19.00  from holding Molecular Partners AG or generate 3.37% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy1.59%
ValuesDaily Returns

Erytech Pharma SA  vs.  Molecular Partners AG

 Performance 
       Timeline  
Erytech Pharma SA 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Erytech Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Erytech Pharma is not utilizing all of its potentials. The newest stock price agitation, may contribute to short-term losses for the retail investors.
Molecular Partners 

Risk-Adjusted Performance

3 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Erytech Pharma and Molecular Partners Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Erytech Pharma and Molecular Partners

The main advantage of trading using opposite Erytech Pharma and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Erytech Pharma position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.
The idea behind Erytech Pharma SA and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Other Complementary Tools

Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance